Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
lungcancers are epithelial tumours that develop from squamous or glandular epithelium (adenocarcinoma) . Lungcarcinoma is also referred to as bronchial carcinoma since this malignanttumour arises from the bronchial epithelium [10, 11]. It is classified into the following main histological types : ? Small cell lungcancer (SCLC; approx. 15%) ? Non-small cell lungcancer (NSCLC; approx. 85%): ? squamous cell carcinoma: spindle cell variant (40%) Extract of rapid report V18-03 Version 1.0 (...) malignanttumours in the lungMalignant lymphomas and sarcomas are canceroustumours that can arise as primary thoracic tumours or as lung metastases . Metastases to the lung often also develop in connection with carcinomas of the colon, rectum, kidney, breast, prostate, and oropharynx . Diffuse malignant pleural mesothelioma originates in the mesothelial or submesothelial cells of the pleura, peritoneum, or pericardium. More than 80% of mesotheliomas originate in the pleura. Mesothelioma
Gibbert ? Thomas Kaiser ? Petra Kohlepp ? Ulrike Lampert ? Katrin Nink Keywords: osimertinib, carcinoma – non-small-cell lung, benefit assessment, NCT02296125 Extract of dossier assessment A18-45 Version 1.0 Osimertinib (non-small cell lungcancer) 11 October 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - 1 - Executive summary of the benefit assessment Background In accordance with §35a Social Code Book (SBG) V, the Federal Joint Committee (G-BA) commissioned the Institute (...) Osimertinib (non-small cell lungcancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Osimertinib (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 October 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English- language readers. However, solely the German original text is absolutely
-small cell lungcancer (NSCLC) whose tumours express programmed cell death ligand-1 (PD-L1) on = 1% of tumour cells and whose disease did not progress following platinum-based chemoradiotherapy. Table 2 presents the research question of the benefit assessment and the ACT specified by the G-BA. Table 2 2 : Research question of the benefit assessment of durvalumab Indication ACT a Adults with locally advanced, inoperable NSCLC whose tumours express PD-L1 on = 1% of tumour cells and whose disease has (...) Durvalumab (locally advanced, unresectable NSCLC) 10 January 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - 2 - Included were adult patients with locally advanced, inoperable NSCLC (stage III according to the International Association for the Study of LungCancer [IASLC] Version 7) with no disease progression following definitive, combined, platinum-based chemoradiotherapy. In the study, 713 patients were randomized, 476 to the intervention arm and 237 to the comparator arm. In both
cancer (MK-3475- 021/KEYNOTE-021): study results [online]. In: ClinicalTrials.gov. 30.01.2019 [Accessed: 16.05.2019]. URL: https://clinicaltrials.gov/ct2/show/results/NCT02039674. Merck Sharp Dohme. A phase 1/2 study of MK-3475 (SCH900475) in combination with chemotherapy or immunotherapy in patients with locally advanced or metastatic non-small cell lungcarcinoma: study P021V03MK3475; clinical study report [unpublished]. 2018. Merck Sharp Dohme. Pembrolizumab KEYNOTE 021G trial platinum therapy (...) Pembrolizumab (non-squamous non-small cell lungcancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Pembrolizumab (nicht plattenepitheliales NSCLC, Kombinationschemotherapie) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 June 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative
: hazard ratio; n: number of patients with at least one event; N: number of analysed patients; NA: not achieved; QLQ-C30: Quality of Life Questionnaire-Core 30; QLQ-LC13: Quality of Life Questionnaire-LungCancer 13; RCT: randomized controlled trial; SAE: serious adverse event; TPS: Tumour Proportion Score; VAS: visual analogue scale; vs.: versus Based on the available data, at most indications, e.g. of an added benefit, can be derived for the outcomes “symptoms” (measured with the EORTC QLQ-C30 (...) Pembrolizumab (squamous non-small cell lungcancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Pembrolizumab (plattenepitheliales NSCLC, Kombinationschemotherapie) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 June 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally
, investigate and refer patients with symptoms that may be lungcancer according to best practice evidence. 32 ` ` Services should have clearly documented pathways and facilitate timely and streamlined referral of patients into the specialist lungcancer team for diagnosis, staging and treatment in line with the national Optimal Care Pathway. 30,31 ` ` Clearly defined evidence-based treatment pathways for patients with lungcancer should be developed according to disease stage. ` ` All patients (...) . 46. Freeman RK, Van Woerkom JM, Vyverberg A, Ascioti AJ. The effect of a multidisciplinary thoracic malignancy conference on the treatment of patients with lungcancer. European Journal of Cardio-Thoracic Surgery. 2010;38(1):1-5. 47. Pillay B, Wootten AC, Crowe H, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treatment Reviews. 2016;42:56-72. 48. Boxer MM, Vinod SK, Shafiq J
Lorlatinib (Lorbrena) - To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lungcancer Drug Approval Package: LORBRENA (lorlatinib) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: LORBRENA (lorlatinib) Company: Pfizer, Inc. Application Number: 210868 Approval Date: 11/02/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter
Patient Navigation Models for LungCancer Rapid Evidence Product Patient Navigation Models for LungCancer eRapid Evidence Product Patient Navigation Models for LungCancer Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2017-00003-C Prepared by: Scientific Resource Center Portland, OR Investigators: Jennifer Gilbert, M.D., M.P.H. Stephanie Veazie, M.P.H. Kevin Joines, B.S (...) , other quality enhancement tools, or reimbursement or coverage policies, may not be stated or implied. Persons using assistive technology may not be able to fully access information in this report. For assistance contact email@example.com. Suggested citation: Gilbert J, Veazie S, Joines K, Winchell K, Relevo R, Paynter R, Guise J-M. Patient Navigation Models for LungCancer. Rapid Evidence Product. (Prepared by Scientific Resource Center under Contract No. 290-2017-00003-C.) AHRQ Publication No. 18(19
30-day mortality after the start of systemic anticancer therapy for lungcancer: is it really a useful performance indicator? Systemic treatment is the standard treatment for unresectable stage III and IV lungcancer. Nevertheless, a 5-10% death rate has been described within 30 days after the last systemic treatment, suggesting that these patient did not benefit. We analysed the 30-day mortality after start of systemic therapy. Data were retrieved from the Netherlands National Cancer Registry (...) . From 2010 to 2015, 26 277 patients were included. 56% were men. The median age was 65 years and 31% of patients were aged ≥70 years. 27% involved small cell lungcancer and 73% nonsmall cell lungcancer. Overall mortality within 30 days after the start of systemic treatment was 6.2%. Multivariable analysis established the prognostic influence of age, histology, number of metastatic sites and type of systemic treatment. Chemotherapy was administered in 77 hospitals, treating each 15-161 lungcancer
? Judith Gibbert ? Thomas Kaiser ? Ulrike Lampert ? Katrin Nink Keywords: atezolizumab, carcinoma – non-small-cell lung, benefit assessment, NCT02008227 Extract of dossier assessment A17-50 Version 1.0 Atezolizumab (non-small cell lungcancer) 27 December 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List of figures v List of abbreviations vi 2 Benefit assessment 1 2.1 Executive summary of the benefit assessment 1 2.2 Research question (...) (Institute for Quality and Efficiency in Health Care) NSCLC non-small cell lungcancer PD-L1 programmed cell death ligand 1 PT Preferred Term QLQ-C30 Quality of Life Questionnaire-Core 30 QLQ-LC13 Quality of Life Questionnaire-LungCancer 13 RCT randomized controlled trial SAE serious adverse event SGB Sozialgesetzbuch (Social Code Book) SPC Summary of Product Characteristics TC tumour cells Extract of dossier assessment A17-50 Version 1.0 Atezolizumab (non-small cell lungcancer) 27 December 2017
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lungcancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study Antibodies targeting the immune checkpoint molecules PD-1 or PD-L1 have demonstrated clinical efficacy in patients with metastatic non-small-cell lungcancer (NSCLC). In this trial we investigated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in patients with NSCLC who had already received platinum-based therapy.JAVELIN Lung (...) 200 was a multicentre, open-label, randomised, phase 3 trial at 173 hospitals and cancer treatment centres in 31 countries. Eligible patients were aged 18 years or older and had stage IIIB or IV or recurrent NSCLC and disease progression after treatment with a platinum-containing doublet, an Eastern Cooperative Oncology Group performance status score of 0 or 1, an estimated life expectancy of more than 12 weeks, and adequate haematological, renal, and hepatic function. Participants were randomly
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell LungCancer Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non-small-cell lungcancer from the phase III FLAURA study. Patients and Methods Patients (N = 556) were randomly assigned (...) , 1.2 to 5.2; P = .011) treated with osimertinib and standard EGFR-TKIs, respectively. Probability of experiencing a CNS progression event was consistently lower with osimertinib versus standard EGFR-TKIs. Conclusion Osimertinib has CNS efficacy in patients with untreated EGFR-mutated non-small-cell lungcancer. These results suggest a reduced risk of CNS progression with osimertinib versus standard EGFR-TKIs.
Anti-tumour effect of low molecular weight heparin in localised lungcancer: a phase III clinical trial The anti-tumour and anti-metastatic properties of heparins have not been tested in patients with early stage cancer. Whether adjuvant low molecular weight heparin (LMWH) tinzaparin impacts the survival of patients with resected non-small cell lungcancer (NSCLC) was investigated.Patients with completely resected stage I, II or IIIA NSCLC were randomly allocated to receive subcutaneous (...) tinzaparin 100 IU·kg-1 once a day for 12 weeks or no treatment in addition to standard of care. The trial was open-label with blinded central adjudication of study outcomes. The primary outcome was overall survival.In 549 patients randomised to tinzaparin (n=269) or control (n=280), mean±sd age was 61.6±8.9 years, 190 (34.6%) patients had stage II-III disease, and 220 (40.1%) patients received adjuvant chemotherapy. Median follow-up was 5.7 years. There was no significant difference in overall survival
of cancer death in both men and women . Smoking is the single greatest risk factor for the development of lungcancer; additional risk factors include radon exposure, occupational exposure to asbestos or other carcinogens, personal history of cancer, family history of lungcancer, history of chronic obstructive pulmonary disease (COPD), and history of pulmonary fibrosis. Both the treatment and prognosis for lungcancer depend upon the stage of the disease, with smaller and less- extensive tumors (...) tending to have longer survivals. The goal of lungcancer screening is to detect early-stage disease before it becomes clinically evident and when appropriate treatment can lead to improved survival. Special Imaging Considerations Unlike conventional chest CT scans performed for other reasons, those done for the purpose of lungcancer screening should be performed using a technique to keep the radiation dose to the patient as low as reasonably achievable. In general, acceptable low-dose lungcancer
is Imfinzi and what is it used for? Imfinzi is a medicine used to treat a type of lungcancer called non-small cell lungcancer (NSCLC). Imfinzi is used in adult patients with advanced cancer that cannot be removed by surgery but is not getting worse after treatment with radiation and platinum-based chemotherapy (medicines to treat cancer). Imfinzi is used specifically when the tumour produces a protein known as PD-L1. Imfinzi contains the active substance durvalumab. How is Imfinzi used? Imfinzi (...) cells and thereby slow down the progression of the disease. Imfinzi (durvalumab) EMA/521637/2018 Page 2/2 What benefits of Imfinzi have been shown in studies? Imfinzi has been shown to be more effective than placebo (a dummy treatment) at prolonging the time patients with advanced non-small cell lungcancer lived without their disease getting worse. In one main study of 713 patients, patients given Imfinzi lived on average for around 17 months without their disease getting worse, compared with 6
the last 25 years, the distribution of histological types of NSCLC has changed: in the United States, squamous cell carcinoma (SCC), formerly the predominant histotype, decreased, while adenocarcinoma has increased in both genders. In Europe, similar trends have occurred in men, while in women, both SCC and adenocarcinoma are still increasing . The World Health Organization (WHO) estimates that lungcancer is the cause of 1.59 million deaths globally per year, with 71% of them caused by smoking (...) . For permissions, please email: firstname.lastname@example.org. Annals of Oncology 29 (Supplement 4): iv192–iv237, 2018 doi:10.1093/annonc/mdy275 Published online 3 October 2018; updated 26 January 2019 Downloaded from https://academic.oup.com/annonc/article-abstract/29/Supplement_4/iv192/5115264 by guest on 26 March 2019have resulted in ‘non-smoking-associated lungcancer’ being con- sidered a distinct disease entity, where speci?c molecular and genetic tumour characteristics have been identi?ed . Use
Bevacizumab (Mvasi) - Metastatic Colorectal Cancer (mCRC) or Locally Advanced, Metastatic or Recurrent Non-small Cell LungCancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product
, distance evaluation). 9. We suggest that low-dose CT screening programs develop strategies to minimize overtreatment of potentially indolent lungcancers. (Ungraded Consensus-Based Statement) Remark: It is important to educate patients about the potential to detect an indolent lungcancer to help mitigate the psychologicaldistress that could resultfrom living with an indolent untreated lungcancer. Remark: For malignant nodules, pure ground glass is the nodule morphology most likely to represent (...) of screen-detected ?ndings, or tolerate treatment of an early-stage screen-detected lungcancer, or that substantially limit their life expectancy, we recommend that low-dose CT screening should not be performed. (Strong recommendation, low-quality evidence) Remark: At very severe stages ofa comorbid condition it can be clear that low-dose CT screening is not indicated (eg, advanced liver disease, COPD with hypoventilation and hypoxia, NYHA class IV heart failure) because competing mortality limits
Smoking and LungCancer Mortality in the United States From 2015 to 2065: A Comparative Modeling Approach. Tobacco control efforts implemented in the United States since the 1960s have led to considerable reductions in smoking and smoking-related diseases, including lung cancer.To project reductions in tobacco use and lungcancer mortality from 2015 to 2065 due to existing tobacco control efforts.Comparative modeling approach using 4 simulation models of the natural history of lungcancer (...) that explicitly relate temporal smoking patterns to lungcancer rates.U.S. population, 1964 to 2065.Adults aged 30 to 84 years.Models were developed using U.S. data on smoking (1964 to 2015) and lungcancer mortality (1969 to 2010). Each model projected lungcancer mortality by smoking status under the assumption that current decreases in smoking would continue into the future (status quo trends). Sensitivity analyses examined optimistic and pessimistic scenarios.Under the assumption of continued decreases